New insider activity at Quest Diagnostics ( (DGX) ) has taken place on November 28, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Vicky Gregg has recently sold 1,250 shares of Quest Diagnostics stock, amounting to a total transaction value of $239,700.
Recent Updates on DGX stock
Quest Diagnostics has seen a series of price target increases from several financial institutions, including Piper Sandler, Truist, Morgan Stanley, and Barclays. These adjustments are primarily driven by positive developments in the company’s diagnostic capabilities, particularly their AD-Detect Alzheimer’s tests, which have demonstrated accuracy in recent studies. The advancements in their testing technology and the potential for increased market share in the diagnostic sector appear to be the key reasons behind the optimistic revisions in price targets.
Spark’s Take on DGX Stock
According to Spark, TipRanks’ AI Analyst, DGX is a Outperform.
Quest Diagnostics receives a strong overall score driven by robust financial performance, positive technical indicators, and a favorable earnings call. The company’s strategic focus on acquisitions and advanced diagnostics supports its growth potential. While valuation is fair, the raised guidance and successful collaborations enhance investor confidence.
To see Spark’s full report on DGX stock, click here.
More about Quest Diagnostics
YTD Price Performance: 28.12%
Average Trading Volume: 1,008,246
Technical Sentiment Signal: Buy
Current Market Cap: $21.1B